Brown tumor is a bone lesion secondary to hyperparathyroidism of various etiologies. Skeletal involvement in primary hyperparathyroidism secondary to parathyroid adenoma is very uncommon and brown tumor has become extremely a rare clinical entity. Hyperparathyroidism is usually associated with high levels of serum calcium. Brown tumor as the only and initial symptom of normocalcemic primary hyperparathyroidism is extremely rare. Moreover, involvement of the skull base and the orbit is exceedingly rare. The authors would report three cases of brown tumor of the anterior skull base that were associated with true normocalcemic primary hyperparathyroidism. Clinical manifestations, neuroimaging findings, pathological findings, diagnosis and treatment of the patients are discussed and the relevant literature is reviewed.
InTRoduCTIon
Brown tumor is a benign reactive destructive process of bone that occurs in patients with either primary or secondary hyperparathyroidism (HPT) (1, 2, 9, 10, 12) . The lesion appears to be relatively rare in the skull base and orbital region (1, 10, 12) . The skull base is composed of membranous bone and has little trabecular bone. Brown tumor usually occurs in the medullary shaft of long bones. Common locations for brown tumor include the mandible, maxilla, clavicle, metacarpal bones, ribs and pelvic bones and rarely the cranium and face (1) . In fact, brown tumor has a minimal affinity for skull base bones. Multiple bone involvements are exceedingly rare in primary HPT and may be mistaken for clinical diagnosis of metastatic lesions (3, 9, 11, 18, 26) .
HPT is a clinical disorder characterized by increase in circulating concentration of parathyroid hormone (PTH) (3, 15, 16, 18, 24) . It is generally classified into primary, secondary, and tertiary depending on its etiology (1, 12, 21) . Primary HPT is usually due to a single parathyroid adenoma (5, 9, 12, 21) . The most common presentation of primary HPT is hypercalcemia which is asymptomatic (10, 11) . There are, however, instances where patients with primary HPT have normal total and/or ionized serum calcium levels or intermittent hypercalcemia (5, 15, 16, 24) . Brown tumor is extremely rare in normocalcemic primary HPT (2, 5, 6, 8, 24) . Only 8 cases have been reported so far in the English literature (Table I) .
The authors present three cases of brown tumors of the anterior skull base which were associated with true normocalcemic primary HPT and presented with brown tumor as the initial and sole manifestation of primary HPT. Clinical manifestations, neuroimaging findings, pathological findings, diagnosis and treatment of this unusual disorder are described and hypotheses of normocalcemia are discussed and the relevant literature is meticulously reviewed. 
CASe RepoRTS

Case 1
A 38-year-old woman was admitted for evaluation of a painful mass in her right orbito-frontal region. She noticed the mass 4 days earlier which appeared suddenly and its size had increased progressively leading to right proptosis and globe deviation inferomedially. Three years earlier, the patient had presented with pain of her right proximal femur. Radiography revealed a large cystic lesion of her right proximal femur. For this reason, she underwent a biopsy and curettage of the lesion with bone graft. Pathological examination reported a giant cell tumor. At that time, serum calcium, phosphorus and alkaline phosphatase (ALP) were within normal ranges and she was not evaluated regarding the presence of HPT. Two years earlier, she once more presented with pain and a large mass of her left maxilla and underwent an excisional biopsy and left maxillotomy with reconstruction. The mass was diagnosed as a giant cell tumor. Again serum calcium, phosphorus, and ALP levels were within normal ranges and she was not evaluated for HPT.
The current examination revealed that the mass had caused right proptosis, ptosis and swelling of her right orbito-frontal region. Plain skull x-ray showed three lytic lesions in the frontal bone and destruction of the right orbital roof. 
Case 3
A 65-year-old woman was referred for evaluation of a painful mass in the right lateral orbital wall and temporalis fossa that had developed four months earlier. The size of the mass had progressively increased and had caused mild proptosis. Physical examination showed a painful swelling on the right lateral orbital region and temporalis fossa. The results of the rest of the physical examinations were normal. CT scan of the brain revealed a well-defined bone-destroying mass involving the lateral wall and roof of the orbit. The mass was isodense with the brain parenchyma, had well-defined sclerotic border and invaded the lateral wall of the right orbit and temporalis fossa. The lesion mainly located on the greater wing of the sphenoid showed extensions into the zygomatic bone, temporalis fossa, and orbit. The MRI showed a hypointense signal on T 1 W images and nonhomogeneous hyperintense signal on T 2 W images. Coronal section showed invasion into the anterior cranial fossa. The lesion enhanced homogeneously after contrast medium injection ( Figure 3A , B). Laboratory evaluation revealed normal serum calcium (both total and ionized), normal phosphorus and ALP. 24-hour urinary calcium assay was normal and 25-OH vitamin D level was 8 ng/mL (normal: 10 to 55 ng/mL). Other laboratory tests were in their normal ranges.
The lesion was removed completely through a pterional (frontotemporosphenoidal) approach. The pathological examination revealed giant cell tumor. Further investigation disclosed a serum PTH value of 820 pg/mL. Ultrasonography of the neck revealed an enlargement of the lower right parathyroid gland (18×11 mm). MRI of the neck showed a parathyroid adenoma. Histo-pathologic examination of the surgically excised specimen confirmed the diagnosis
Case 2
A 35-year-old woman was admitted with a complaint of pain and expanding left frontal mass for about 3 months. On examination, a subgaleal mass was found in the left frontal area just above the left orbital rim with mild proptosis. Otherwise, the neurological and physical examinations were normal. CT scan of the brain showed a destructive expansile lesion of the frontal sinus with erosion of both internal and external tables of the frontal bone and frontal sinus and left orbital roof and extension through the skull in the intracranial and subgaleal spaces (Figure 2A) . MRI of the brain revealed a large frontal mass involving the frontal sinus, isointense on T 1 W images and heterogeneous hyperintense on T 2 W images with subgaleal extension. The lesion enhanced homogeneously after contrast medium injection ( Figure  2B ). Laboratory studies revealed normal serum levels of total calcium (8. Our first case brings the number of multiple brown tumors in primary HPT patients to 12 cases. Only the current case had normocalcemic primary HPT with multiple brown tumors.
Involvement of the orbito-frontal region and the skull base is considered rare (1, 12, 17, 25, 27) . In the skull base, they usually involve one or more of the paranasal sinuses. The most commonly involved sinus is maxillary sinus and the frontal sinus is the least commonly involved, with the sphenoidal and ethmoidal sinuses lying somewhere in between (1). AlGahtany et al. (1) These tumors are usually soft, painless, minimally tender, and appear elastic on palpation (1, 5, 10, 24) . Occasionally, the lesion is painful (6, 10, 12), as was seen in our cases. The tumor is called "brown" because of its color, which is a result of vascularity, hemorrhage and deposit of hemosiderin (5, 6, 9, 12, 23).
Most patients with primary HPT (80-85%) show a single adenoma in one parathyroid gland whereas the other 3 glands are normal as was observed in our patients. Approximately 15% to 20% of patients have a pathological process (hyperplasia) involving all four parathyroid glands (9, 12, 21, 25) .
Since the major action of PTH is to raise plasma calcium level, the main biochemical abnormality in primary HPT is of parathyroid adenoma. The postoperative course was uneventful, and PTH levels returned to normal ranges and at 3 years after surgery, no recurrence of the tumor was detected.
dISCuSSIon
The differential diagnoses of bone-expanding or lytic lesions in the skull base include plasmacytoma, metastatic lesions, fibrous dysplasia, primary bone tumors, inflammatory lesions and giant cell lesions. Bone expanding giant cell lesions that can arise in the skull base include true giant-cell tumor, aneurysmal bone cyst, giant cell reparative granuloma and brown tumor (1, 12, 25, 27) .
Brown tumor represents localized accumulation of fibrous tissue and giant cells, which can replace bone and may even produce osseous expansion and subsequently undergo necrosis and liquefaction, producing cysts as a result of intraosseous bleeding and tissue degeneration (1, 5, (9) (10) (11) (12) .
These tumors are considered as the end-stage complication of HPT and are rarely the first presentation of the disease (25) . They are relatively rare today, due to earlier diagnosis and prompt treatment of HPT, and are seen more often as a result of secondary HPT because of an increasing number of dialysis patients and their increased longevity (1, 9-13, 23, 24) . 
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be seen in normocalcemic patients as well (5), as in our cases. Histologically, brown tumors are non-encapsulated and are characterized by abundant stroma consisting of fibrous connective tissue, with an important proliferation of fibroblasts and several multinucleated osteoclast-like giant cells containing variable numbers of nuclei. Calcified material and areas with extravasations of red blood cell and hemosiderin in histiocyte can be found (9, 11, 12, (22) (23) (24) (25) .
The clinical features of calvarial brown tumors are non-specific and depend on their size and location. Headache, swelling, and ophthalmological symptoms such as diplopia, ptosis, decreased visual acuity, decreased extraocular movement, proptosis and pain are the most common symptoms associated with skull base brown tumors (1, 12, 17, 23, 25, 27) .
Radiographically, brown tumors are usually well-defined purely lytic unilocular or multilocular lesions that stimulate little reactive bone formation (22, 26) . The pathologically similar giant cell tumors often have indistinct borders and blend into the normal bone, a finding that may serve to distinguish them from brown tumors (1, 10, 11, 12, (22) (23) (24) . Characteristic radiographic finding of HPT can also be found in patients with brown tumors such as widespread loss of lamina dura, and subperiosteal erosion of phalanges (2, 22, 23, 25) . However, occasionally a solitary brown tumor is the only skeletal manifestation of HPT (22), as in our cases two and three. On CT scan, brown tumors appear as a lytic lesion with associated soft tissue mass. The lesion may be hyperdense or heterogeneous, and well-circumscribed or expansile lucent lesion with a rim of calcification and remodeling of surrounding bone. After injection of contrast medium, brown tumors appear as heterogeneously enhancing masses (1, 9, 11, 13, (22) (23) (24) (25) 27) . There is no periosteal reaction or soft tissue invasion (11, 22) . The appearance on CT is not specific, and metastasis or myeloma may have a similar appearance (13, 26) . The brown tumor may demonstrate fluid-fluid level consisting with internal hemorrhage on CT scan (9, 27) , as was seen in our first patient.
On MR imaging, brown tumors usually have hypointense signal on T 1 W images, variable signal on T 2 W images, and loss of signal on in-phase images because of magnetic susceptibility related to hemosiderin, osteoid matrix or air within the tissue (9, 13, 22, 23) . Brown tumors enhance intensely after contrast injection (1, 9, 13, 22, 23) . The early and intense enhancement is due to rich vascularity (22) . The wide spectrum features of brown tumor on MRI depend on the pathologic background and tissue component of tumor such as cystic area, hemorrhage, fibrous stroma, and hemosiderin deposition (13, 22, 23) . Repeated episode of intratumoral hemorrhage led to fluid-fluid levels (22) , as in our cases.
When an osteolytic lesion of the skull base is diagnosed, especially when it is a giant cell tumor, even with a normal serum calcium level, PTH assay is necessary to exclude HPT. Treatment of brown tumor should start with treatment of HPT (removal of offending adenoma) and if persisted after this primary treatment, enucleation and curettage should an increase in the circulating concentrations of both PTH and calcium (16) . Some patients with proven parathyroid adenoma have normal total and/or ionized serum calcium level or intermittent hypercalcemia (15, 16) . Approximately 20% of patients with primary HPT are normocalcemic. When the ionized calcium concentration is normal, the term truly normocalcemic is applied. Approximately 20% of patients with normocalcemic primary HPT are true normocalcemic (15, 16) , as in our cases.
Several hypotheses have been proposed to explain the persistently normocalcemia in primary HPT (15, 16):
1. In normocalcemic primary HPT, serum total calcium concentration is normal but, free (ionized), biologically relevant fraction of serum calcium is increased.
2. Normocalcemia in these patients may represent an early and/or a mild variety of primary HPT.
3. Normocalcemia could be the consequence of a renal tubular resistance to the action of PTH. Patients with normocalcemic primary HPT have a normal tubular reabsorption of calcium.
4. The mass of parathyroid adenoma is smaller in normocalcemic patients, thus, mean serum PTH concentration is lower.
5.
A primary renal calcium leak leading to secondary hyperparathyroidism and eventually autonomous hyperparathyroidism has been proposed.
6. Concomitant vitamin D deficiency and/or insufficient calcium intake has been proposed to account for persistent normocalcemia in primary HPT.
7. Serum calcium levels before developing HPT is lower in these patients and that they increased but stay within the normal range.
Normal calcium (total and ionized) level, low normal serum vitamin D level and the presence of multiple brown tumors show the coincidence of osteoporosis and long and severe primary HPT in our first case. Normal calcium (total and ionized) level, low serum vitamin D and brown tumor show the coincidence of primary HPT with vitamin D deficiency in our second and third cases. Parathyroid adenoma and high PTH level indicate the presence of primary HPT. Vitamin D deficiency, osteomalacia, and osteoporosis are common findings in developing countries and when compounded by primary HPT, become a diagnostic challenge and a cause of apparent normocalcemic HPT. The majority of patients with normocalcemic primary HPT have a history of urinary tract stone and/or hypercalciuria, but brown tumor without renal calculi also occur in these patients (8, 19, 24) , as was observed in our patients.
The diagnosis of HPT should be established by determination of the serum calcium, phosphorus, ALP, and PTH level rather than by histological examination of focal lesion. The main challenge in diagnosing brown tumor is that it can be added. Compressive lesions with neural compromise, functional problem and fracture may require early surgical removal (1, 2, 5, 9, 10, 12, (21) (22) (23) 25) . Sometimes, surgery is indicated for definitive tissue diagnosis. In patients with primary HPT or normocalcemia, in whom the brown tumor is the first manifestation, biopsy is necessary (1).
There is limited evidence about natural history of brown tumor in the skull base. According to a report, brown tumor of the ethmoidofrontal skull base, in a 38-year-old woman with parathyroid adenoma who underwent parathyroid adenectomy, underwent extensive calcification after 6 years and the patient became asymptomatic. This pattern has been reported in other parts of the skeleton. When parathyroid adenoma is removed and consequently serum level of parathormone and calcium decrease, brown tumors rarely progress (1).
In conclusion, brown tumors of the anterior skull base region are rare. They are extremely rare in normocalcemic primary HPT. The point in reporting these cases is that they may be the first clinical sign of HPT. To prevent unnecessary surgical procedures, PTH assay is necessary in any patient with expansive-lytic lesion or giant cell tumor of the skull base.
ABBRevIATIonS pTH = parathyroid hormone, HpT = hyperparathyroidism, ALp = alkaline phosphatase.
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